Search
Tuoxin Pharmaceutical has announced a strategic investment of tens of millions of yuan in Jiangsu-based TsingSan Bio, using its own funds and signing a cooperation agreement. This latest funding round follows closely on the heels of TsingSan Bio's successful completion of a Pre-A round, which raised hundreds of millions of yuan. This rapid succession of financing underscores the capital market's unwavering optimism regarding the industrialization potential of ergothioneine. TsingSan Bio specializes in the research and development of ergothioneine, having achieved a breakthrough in high-purity preparation technology. Its product portfolio encompasses a diverse range, including skin care products and oral capsules. Tuoxin Pharmaceutical's investment is aimed at extending the industrial chain and bolstering TsingSan Bio's market competitiveness.
-
C114 Communication Network -
Communication Home
